Isocitrate dehydrogenase (IDH) mutation status has emerged as one of the most important molecular markers for glioma diagnosis and therapy, and the early determination of IDH mutation status directly impacts treatment decisions3,4. This evidence concerns the gene IDH1 and central nervous system cancer.